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The design and synthesis of metal-based anti-tumor drugs have
been extensively studied following the discovery of the anticancer
activity of cisplatin by Rosenberg [1], which remains the most
commonly used anti-tumor drug in the world [2]. The quest for
other platinum-based drugs arises from the high toxicity of cis-
platin which gives rise to unwanted side effects and consequently
limits its administered dose [3], and the resistance of some tumors
to cisplatin [4]. In addition to the development of platinum drugs,
other metal-based anticancer agents have been developed, which
combine good cytotoxic activity with reduced general toxicity
and side effects. In this respect, iron and ruthenium-based drugs
appear to be good alternatives to platinum drugs, and considerable
advances have been made on anticancer drugs based on these met-
als [5,6], taking into account that iron and ruthenium compounds
are well tolerated in vivo, and exhibit low general toxicity com-
pared to their platinum counterparts. For ruthenium, this feature
has been ascribed to two main reasons: ﬁrst, the accumulation of
ruthenium compounds in tumors, due to the ability of rutheniumax: +41 (0) 32 718 25 11.
Fink).to mimic iron in binding to transferrin (receptors of transferrin
are over-expressed on cancer cells) [7,8]; and second, the well-
accepted phenomena of ‘‘activation by reduction” from Ru(III)?
Ru(II) in vivo, which is favored in the hypoxic environment of a
tumor [7].
It has been shown that simple ferrocene compounds exhibit
good cytotoxicities in vitro and inhibit the development of tumors
in vivo [9]. Jaouen has shown that appending the ferrocenyl unit to
biologically active molecules led to complexes with an increased
potency and tumor speciﬁcity possibly due to the combined action
of the organic molecule with Fenton chemistry of the Fe center
[10]. Ferrocene has been linked to others transition-metals such
as platinum [11,12] and gold [13] centers in order to achieve syn-
ergic effects between the two active metals.
Arenes are known to stabilize ruthenium in its +2 oxidation
state, the active form of such complexes, therefore arene–ruthe-
nium complexes have become intensively studied anticancer
agents in recent years. The ﬁrst complex evaluated was [Ru(g6-
benzene)(metronidazole)Cl2], which presented a higher activity
compared to the anti-tumor drug metronidazole itself [14], and
more recently [Ru(g6-arene)(pta)Cl2] [15] (pta = 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane), [Ru(g6-arene)(YZ)Cl][PF6] [16]
(YZ = chelating diamine) as well as dinuclear compounds [17],
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C6H6)(g6–C6Me6)2O]+ and [H4Ru4(g6–C6H6)4]2+ have been studie
in vitro for their activity.
In a recent study arene–ruthenium fragments coordinated t
pyridyl-ferrocene ligands [20] were found to exhibit good cytotoxr-
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Scheme 2. Synthesicities against A2780 and A2780cisR (cisplatin resistant) ovaria
carcinoma cell lines, and subsequently we designed a new serie
of arene–ruthenium complexes containing ferrocene-derived l
gands. In this paper we describe these new compounds of gener
formula [Ru(g6-arene)Cl2]n(L) bearing terminal (n = 1), or bridgin
(n = 2) ferrocene derivatives as ligands L. The synthesis, characte
ization, and in vitro cytotoxic activity on A2780 cell line of thes
ferrocene-containing arene–ruthenium complexes, and the free l
gands, are reported.
2. Results and discussion
2.1. Synthesis and characterization of 1–4
In order to access new potential cytotoxic arene–Ru(II) com
plexes coordinated to ferrocene-derived ligands the four followin
ligands were designed. The ligands L1 and L3 contain pyridyl con
nectors for coordination to ruthenium, and ligands L2 and L4 con
tain imidazolyl connectors (Chart 1).
The complexes [Ru(g6-arene)Cl2]2 (arene = p-iPrC6H4Me o
C6Me6) [21] react in dichloromethane at room temperature wit
two equivalents of the pyridyl-ferrocene ligand (NC5H4CH2NHOC
C5H4FeC5H5) L1 to afford the complexes [Ru(g6-p-iPrC6H4
Me)(L1)Cl2] (1) and [Ru(g6–C6Me6)(L1)Cl2] (2), respectively. Th
analogous reaction between the arene–ruthenium complexes an
the imidazolyl-ferrocene ligand (NC3H3N(CH2)2O2C–C5H4FeC5H
L2 affords the complexes [Ru(g6–p-iPrC6H4Me)(L2)Cl2] (3) an
[Ru(g6–C6Me6)(L2)Cl2] (4) (Scheme 1). In contrast, the reaction o
[Ru(g6-arene)Cl2]2with 1 equiv. of the dipyridyl-ferrocene ligan
(1,10-(NC5H4CH2NHOC)2–C5H4FeC5H4) L3 gives [Ru(g6–p-iPrC6H4
Me)Cl2]2(L3) (5) and [Ru(g6–C6Me6)Cl2]2(L3) (6) and the reactio
with 1 equiv. of the di-imidazolyl-ferrocene ligand (1,1
(NC3H3N(CH2)2O2C)2–C5H4FeC5H4) L4 yields [Ru(g6–p-iPrC6H4
Me)Cl2]2(L4) (7) and [Ru(g6–C6Me6)Cl2]2(L4) (8) (Scheme 2). A
the products are obtained by precipitation as air-stable orange t
red powders (see Section 3).
Compounds 1–8 are soluble in halogenated solvents and pola
organic solvents such as tetrahydrofuran, methanol or dimethy
sulfoxide and also slightly soluble in water. All complexes wer
characterized by 1H and 13C{1H} NMR spectroscopy, by mas
spectrometry as well as by elemental analysis (see Section 3).5
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3The single-crystal X-ray structure analysis of 1 conﬁrms the ex-
pected structure which is presented in Fig. 1 with selected bond
parameters. The ruthenium center in 1 possesses a pseudo-octahe-
dral geometry and the ferrocene adopts an eclipsed conformation.
The metric parameters around the metallic core compare well with
those of the ”ester” analogue [Ru(g6–p-iPrC6H4Me)(NC5H4O2C–
C5H4FeC5H5)Cl2] and other related imidazolyl species [22].
In the crystal packing of 1, two molecules form a dimeric struc-
ture through N–H  Cl and C–H   Cl hydrogen-bonds and p-stack-Fig. 1. ORTEP diagram of complex 1  CHCl3. Hydrogen atoms and solvating CHCl3
molecule are omitted for clarity. Selected bond lengths (Å) and angles (): Ru1–Cl1
2.397(2), Ru1–Cl2 2.408(2), Ru1–N1 2.131(4), N2–C16 1.452(7), N2–C17 1.351(8),
C17–O1 1.233(7), C17–C18 1.483(7), Cl1–Ru1–Cl2 87.85(6), N1–Ru1–Cl1 87.01(14),
N1–Ru1–Cl2 85.67(13), C16–N2–C17 120.0(5), O1–C17–N2 121.9(5), O1–C17–C18
120.9(6).
2.79 Å 
2.48 Å 
Fig. 2. Dimeric structure of 1 showing the hydrogen-bonded network and thing interactions between the parallel aromatic rings of two
adjacent complexes, see Fig. 2. The centroid–centroid separation
of the slipped parallel p-interacting system is 4.23 Å, while the
N  Cl and C  Cl distances of the hydrogen-bonds are 3.301(5)
and 3.595(6) Å with N–H  Cl and C–H  Cl angles of 160.6 and
145.3, respectively.
Complex 3 crystallizes with two independent molecules per
asymmetric unit, see Fig. 3. In both forms the ferrocene is found
in an eclipsed conformation and the ruthenium center adopts a
pseudo-octahedral geometry. The bond lengths and angles ﬁt
well with those of 1 and other analogues [20,22] although the
spatial orientation of the ferrocene unit differs signiﬁcantly be-
tween the two independent molecules. Indeed, in the ﬁrst mol-
ecule, the ferrocene group points away from the p-cymene
ligand, while in the second molecule, the ferrocene group faces
the p-cymene ligand. Thus, in the crystal packing of 3, the two
ferrocene units face one another in a staggered conformation:
the iron–iron distance between the two ferrocene units being
5.4566(8) Å.
2.2. Cytotoxicity of L1–L4 and 1–8
The cytotoxicity of the ligands L1–L4 and complexes 1–8 to-
wards the A2780 ovarian cancer cell line was evaluated in vitro
using the MTT assay which measures mitochondrial dehydroge-
nase activity as an indication of cell viability (see Section 3). The
compounds are incubated at various concentrations in the A2780
cells and the cell viability measured after an incubation period of
72 h. Each experiment is conducted in duplicate and the IC50 values
listed in Table 1 are calculated as an average over the two
experiments.
The ligands L1–L4 have IC50 values all greater than 329 lM,
whereas the complexes 1–8 are more cytotoxic with IC50 values
in the range 103–390 lM. Although the complexes can be de-
scribed as only slightly cytotoxic towards A2780 cancer cells, they
are more active than other ruthenium compounds described in the
literature such as [Ru(g6–p-iPrC6H4Me)(pta)Cl2] (>300 lM) [23a]
and [Ru(g5–C5H5)(pta)2Cl] (>1000 lM) [23b].4.23 Å 2.48 Å 
2.79 Å 
e intermolecular p-stacking interaction (symmetry code: 1x, 1y, z).
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Fig. 3. ORTEP diagram of the two forms present in the crystal of complex 3. Hydrogen atoms are omitted for clarity. Selected bond lengths (Å) and angles () for the Ru1
molecule: Cl1–Ru1 2.4153(9), Cl2–Ru1 2.4229(9), N1–Ru1 2.119(2), C32–O2 1.446(4), C31–O1 1.198(4), C26–C31 1.473(5), Cl1–Ru1–Cl2 85.82(4), N1–Ru1–Cl1 88.65(7). N1–
Ru1–Cl2 81.45(8), C35–N1–Ru1 128.6(2), C36–N1–Ru1 123.5(2), C31–O2–C32 115.2(3), O1–C31–O2 123.2(3), O1–C31–C26 125.2(4), C33–C32–O2–C31 168.0(3), O2–C32–
C33–N2 57.9(4), C26–C31–O2–C32 170.7(3). Selected bond lengths (Å) and angles () for the Ru2 molecule: Cl3–Ru2 2.4251(9), Cl4–Ru2 2.4273(9), N3–Ru2 2.131(2),
C52–O4 1.444(4), C51–O3 1.209(4), C46–C51 1.450(5), Cl3–Ru2–Cl4 87.04(3), N3–Ru2–Cl3 83.97(8), N3–Ru2–C14 106.09(12), C55–N3–Ru2 126.5(2), C56–N3–Ru2 127.2(2),
C51–O4–C52 115.5(2), O3–C51–O4 122.6(3), O3–C51–C46 125.7(3), C53–C52–O4–C51 170.6(3), O4–C52–C53–N4 –78.9(4), C46–C51–O4–C52–179.4(3).
Table 1
IC50 values of ligands L1–L4 and complexes 1–8 in A2780 human ovarian cancer cells
after 72 h
Compound IC50 (lM)
L1 329
L2 335
L3 >500
L4 410
1 390
2 225
3 130
4 103
5 341
6 235
7 230
8 170
4Some structure–activity relationships can be made from a
analysis of 1–8. For each pair of related complexes the hexamethy
benzene derivative is more active than the p-cymene derivativ
presumably due to the greater hydrophobicity of the hexamethy
benzene ring which facilitates transport of the complex into th
cancer cell. Furthermore, the imidazolyl-linked complexes ar
more cytotoxic than their related pyridyl-linked counterpart
The reason for this could be related to the differences in th
strength of these different groups to coordinate to the arene
ruthenium(II) fragment, differences in the transmission o
electronic effects between the metal centers or due to the relativ
stability of the amide and ester bonds. Other arene–ruthenium
complexes with imidazolyl-groups have been reported and als
show interesting in vitro characteristics [24]. The higher cytotoxic
ities of the ester-linked complexes relative to the amide-linke
systems could be a consequence of the ester-linkage which is mor
prone to hydrolytic cleavage by esterases present in the cell cyto
plasm [25]. Potentially, the release of the ferrocene unit activates
once inside the cell.
It is particularly interesting that the complexes containing tw
arene–ruthenium fragments (5–8) have similar activities to th
mono-ruthenium complexes (1–4). However, this result contras
with the results obtained for arene–ruthenium complexe
connected via a shorter linkage [20] which were about twice acytotoxic as compared to their mononuclear counterparts. Thes
complexes were also more cytotoxic than the compounds reporte
herein with IC50 values in the range 15–50 lM in the same cell lin
Despite the low cytotoxicities of 1–8 a number of ruthenium
based compounds have been found to show very good in viv
activity although they display only a low in vitro cytotoxicit
[15,26]. Indeed, there does not appear to be a close correlation be
tween in vitro and in vivo activity for ruthenium compounds an
alternative assays that avoid use of animals are under developmen
[27].
3. Experimental
3.1. General remarks
All reagents were purchased either from Aldrich or Fluka an
used as received. The complexes [Ru(g6-arene)Cl2]2, ferrocene ca
boxylic acid chloride and 1,10-ferrocene dicarboxylic acid chlorid
were prepared according to literature methods [22,28]. NMR spec
tra were recorded on a Bruker AMX 400 spectrometer using th
residual proton resonance of the deuterated solvent as an intern
standard. Elemental analyses were performed by the Laboratory o
Pharmaceutical Chemistry, University of Geneva (Switzerland) o
by the Mikroelementaranalytisches Laboratorium, ETH Züric
(Switzerland). Electrospray mass spectra were performed by th
Service Analytique Facultaire of the University of Neuchât
(Switzerland).
3.1.1. Synthesis of ligands L1–L4
3.1.1.1. (NC5H4CH2NHOC–C5H4FeC5H5) (L1). In a Schlenk tube,
solution of ferrocene carboxylic acid (1 g, 4.34 mmol), N,N0-dicyclo
hexylcarbodiimide (1.67 g, 8.69 mmol), 4-(dimethylamino
pyridine (1.06 g, 8.69 mmol), 4-pyrrolidinopyridine (1.29
8.69 mmol) and 4-picolylamine (1.32 mL, 13.04 mmol) was dis
solved in anhydrous dichloromethane (50 mL). The solution wa
stirred under inert atmosphere at room temperature for 2 day
then the solution was ﬁltered on celite and the product was ob
tained as an orange powder after puriﬁcation on silica gel (eluen
methanol/ethyl acetate 1:2). Yield: 54%, 753 mg. 1H NM
(400 MHz, CDCl3): d = 8.60 (d, 2H, NC5H4, 3J = 6.0 Hz), 7.28 (d, 2H
5NC5H4, 3J = 6.0 Hz), 6.09 (br, 1H, NH), 4.71 (t, 2H, CHFc, 3J = 2.0 Hz),
4.59 (d, 2H, NHCH2, 3J = 6.0 Hz), 4.39 (t, 2H, CHFc, 3J = 2.0 Hz), 4.21
(s, 5H, CHFc). 13C{1H} NMR (100 MHz, CDCl3): d = 170.61 (CONH),
150.15 (NC5H4), 147.93 (NC5H4), 122.38 (NC5H4), 95.0, 70.74,
69.78, 68.18 (CHFc), 42.41 (CH2). ESI-MS: m/z = 321.1 [M+H]+.
3.1.1.2. (NC3H3N(CH2)2O2C–C5H4FeC5H5) (L2). In a Schlenk tube,
freshly prepared ferrocene carboxylic acid chloride (1 g, 4.0 mmol),
1-(2-hydroxyethyl)imidazole (542 mg, 4.48 mmol) and triethyl-
amine (3 mL) were dissolved in anhydrous dichloromethane
(30 mL). The solution was stirred under an inert atmosphere at
room temperature for 3 days, then the solution was ﬁltered on cel-
ite and the product was obtained as an orange powder after puri-
ﬁcation on silica gel (eluent: CH2Cl2/acetone 1:1). Yield: 48%,
680 mg. 1H NMR (400 MHz, CDCl3): d = 7.61 (s, 1 H, NC3H3N),
7.13 (s, 1H, NC3H3N), 7.05 (s, 1H, NC3H3N), 4.78 (t, 2H, COOCH2,
3J = 1.8 Hz), 4.47 (t, 2 H, CHFc, 3J = 5.2 Hz), 4.43 (t, 2H, COOCH2CH2,
3J = 1.8 Hz), 4.30 (t, 2H, CHFc, 3J = 5.2 Hz), 4.14 (s, 5H, CHFc). 13C{1H}
NMR (100 MHz, CDCl3): d = 171.44 (COO), 137.55 (NC3H3N), 129.97
(NC3H3N), 118.98 (NC3H3N), 71.70, 70.15, 69.94, 69.87 (CHFc),
63.02 (CH2), 46.01 (CH2). ESI-MS: m/z = 347.05 [M+Na]+.
3.1.1.3. (1,10-(NC5H4CH2NHOC)2–C5H4FeC5H4) (L3). In a Schlenk
tube, freshly prepared 1,10-ferrocene dicarboxylic acid chloride
(500 mg, 1.61 mmol), 4-picolylamine (0.65 mL, 6.43 mmol) and
1 mL of triethylamine were dissolved in anhydrous dichlorometh-
ane (30 mL). The solution was stirred under inert atmosphere at
room temperature for 6 h, then the solution was ﬁltered on celite
and the product was obtained as a red powder after puriﬁcation
on silica gel (eluent: ethanol). Yield: 47%, 344 mg. 1H NMR
(400 MHz, CDCl3): d = 8.54 (d, 4H, NC5H4, 3J = 6.0 Hz), 7.58 (t, 2H,
NH, 3J = 6.0 Hz), 7.27 (d, 4 H, NC5H4, 3J = 6.0 Hz), 4.55 (d, 4H,
NHCH2, 3J = 6.0 Hz), 4.51 (t, 4H CHFc, 3J = 2.0 Hz), 4.39 (t, 4H, CHFc,
3J = 2.0 Hz). 13C{1H} NMR (100 MHz, CDCl3): d = 170.93 (CONH),
149.98 (NC5H4), 147.82 (NC5H4), 122.55 (NC5H4), 78.05, 71.19,
70.94 (CHFc), 42.59 (CH2). ESI-MS: m/z = 477.10 [M+Na]+.
3.1.1.4. (1,10-(NC3H3N(CH2)2O2C)2–C5H4FeC5H4) (L4). In a Schlenk
tube, freshly prepared 1,10-ferrocene dicarboxylic acid chloride
(500 mg, 1.61 mmol), 1-(2-hydroxyethyl)imidazole (721 mg,
6.43 mmol) and pyridine (0.5 mL) were dissolved in anhydrous
dichloromethane (30 mL). The solution was stirred under inert
atmosphere at room temperature for 6 h, then the solution was ﬁl-
tered on celite and the product was obtained as a red powder after
puriﬁcation on silica gel (eluent: ethanol). Yield: 36%, 267 mg. 1H
NMR (400 MHz, CDCl3): d = 7.69 (s, 2 H, NC3H3N), 7.17 (s, 2H,
NC3H3N), 7.10 (s, 2H, NC3H3N), 4.72 (s, 4H, CHFc), 4.46 (t, 4H,
COOCH2, 3J = 5.2 Hz), 4.36 (s, 4H, CHFc), 4.32 (t, 4H, COOCH2CH2,
3J = 5.2 Hz). 13C{1H} NMR (100 MHz, CDCl3): d = 169.79 (COO),
137.95 (NC3H3N), 129.92 (NC3H3N), 119.04 (NC3H3N), 73.05,
72.01, 71.72 (CHFc), 63.13 (CH2), 46.16 (CH2). ESI-MS: m/
z = 463.13 [M+H]+.
3.1.2. Synthesis of complexes 1–4
3.1.2.1. Synthesis of [Ru(g6-arene)(L)Cl2]. To a solution of [Ru(g6-
arene)Cl2]2(100 mg) in dichloromethane (20 mL), 2 equiv. of solid
L1 or L2 were added (1 and 3: 0.325 mmol, 2 and 4: 0.3 mmol).
The mixture was stirred at room temperature for 24 h. The product
was isolated by precipitation with diethyl ether and dried in vacuo
to afford an orange to red powder.
3.1.2.2. [Ru(g6-p-iPrC6H4Me)(NC5H4CH2NHOC–C5H4FeC5H5)Cl2]
(1). Yield: 86%, 176 mg. 1H NMR (400 MHz, CDCl3): d = 8.63 (d,
2H, NC5H4, 3J = 6.0 Hz), 7.53 (br, 1H, NH), 7.02 (d, 2H, NC5H4,
3J = 6.0 Hz), 5.42 (d, 2 H, C6H4, 3J = 6.0 Hz), 5.14 (d, 2H, C6H4,
3J = 6.0 Hz), 4.94 (s, 2H, CHFc), 4.32 (s, 2H, CHFc), 4.20 (s, 5H, CHFc),4.11 (d, 2H, NHCH2, 3J = 5.2 Hz), 3.00 (sept, 1H, CH(CH3)2,
3J = 7.0 Hz), 1.99 (s, 3H, CH3), 1.31 (d, 6H, CH(CH3)2, 3J = 7.0 Hz).
13C{1H} NMR (100 MHz, CDCl3): d = 171.24 (CONH), 153.85
(NC5H4), 152.85 (NC5H4), 122.33 (NC5H4), 103.88 (C–CH(CH3)2),
97.21 (C–CH3), 83.15, 82.16 (C6H4), 75.72, 70.64, 69.94, 69.15
(CHFc), 41.56 (CH2), 30.90 (CH(CH3)2), 22.46 (CH(CH3)2), 18.42
(CH3). ESI-MS: m/z = 626.9 [M+H]+. Anal. Calc. for C27H30FeN2OR-
uCl2 (626.36) C, 51.77; H, 4.83; N, 4.47. Found: 51.42; H, 4.89; N,
4.20%.
3.1.2.3. [Ru(g6–C6Me6)(NC5H4CH2NHOC–C5H4FeC5H5)Cl2] (2). Yield:
59%, 115 mg. 1H NMR (400 MHz, CDCl3): d = 8.40 (d, 2H, NC5H4,
3J = 6.4 Hz), 7.64 (br, 1H, NH), 7.01 (d, 2H, NC5H4, 3J = 6.4 Hz),
4.94 (t, 2H, CHFc, 3J = 2.0 Hz), 4.29 (t, 2H, CHFc, 3J = 2.0 Hz), 4.19 (s,
5H, CHFc), 4.15 (d, 2H, NHCH2, 3J = 6.0 Hz), 1.93 (s, 18H, CH3).
13C{1H} NMR (100 MHz, CDCl3): d = 170.97 (CONH), 153.23
(NC5H4), 152.28 (NC5H4), 123.22 (NC5H4), 91.25 (C–CH3), 75.91,
70.26, 69.74, 68.94 (CHFc), 41.06 (CH2), 15.46 (CH3). ESI-MS: m/
z = 633.06 [M2Cl+MeOH+H2O]+. Anal. Calc. for
C29H34FeN2ORuCl2  1/5 CH2Cl2 (671.40) C, 52.24; H, 5.16; N, 4.17.
Found: C, 52.27; H, 5.38; N, 4.13%.
3.1.2.4. [Ru(g6-p-iPrC6H4Me)(NC3H3N(CH2)2O2C–C5H4FeC5H5)Cl2] (3).
Yield: 70%, 145 mg. 1H NMR (400 MHz, CDCl3): d = 7.99 (s, 1H,
NC3H3N), 7.31 (s, 1H, NC3H3N), 7.00 (s, 1H, NC3H3N), 5.39 (d, 2H,
C6H4, 3J = 5.6 Hz), 5.20 (d, 2H, C6H4, 3J = 5.6 Hz), 4.81 (s, 2H, CHFc),
4.44 (ps s, 4H, COOCH2, CHFc), 4.18 (ps s, 7H, COOCH2CH2, CHFc),
2.94 (sept, 1H, CH(CH3)2, 3J = 6.8 Hz), 2.12 (s, 3H, CH3), 1.24 (d, 6
H, CH(CH3)2, 3J = 6.8 Hz). 13C{1H} NMR (100 MHz, CDCl3):
d = 171.50 (COO), 140.41 (NC3H3N), 132.35 (NC3H3N), 120.17
(NC3H3N), 102.85 (C–CH(CH3)2), 97.39 (C–CH3), 82.59, 81.65
(C6H4), 72.03, 70.44, 70.12, 69.95 (CHCp), 62.68 (CH2), 47.53 (CH2),
30.84 (CH(CH3)2), 22.44 (CH(CH3)2), 18.70(CH3). ESI-MS: m/
z = 595.06 [MCl]+. Anal. Calc. for C26H30FeN2O2RuCl2 (630.35) C,
49.54; H, 4.80; N, 4.44. Found: C, 49.40; H, 4.87; N, 4.35%.
3.1.2.5. [Ru(g6–C6Me6)(NC3H3N(CH2)2O2C–C5H4FeC5H5)Cl2] (4). Yield:
63%, 124 mg. 1H NMR (400 MHz, CDCl3): d = 7.81 (s, 1H, NC3H3N),
7.37 (s, 1H, NC3H3N), 7.12 (s, 1H, NC3H3N), 4.80 (m, 4H, CH2, CHFc),
4.40 (m, 4H, CH2, CHFc), 4.19 (s, 5H, CHFc), 1.96(s, 18H, CH3).
13C{1H} NMR (100 MHz, CDCl3): d = 171.24 (COO), 139.48 (NC3H3N),
131.56 (NC3H3N), 118.98 (NC3H3N), 90.75 (C-CH3), 71.82, 70.22,
69.96, 69.86 (CHFc), 62.69 (CH2), 47.15 (CH2), 15.58 (C–CH3). ESI-
MS: m/z = 623.07 [MCl]+. Anal. Calc. for C28H34FeN2O2RuCl2
(658.40) C, 51.08; H, 5.21; N, 4.25. Found: C, 51.24; H, 5.32; N, 4.14%.
3.1.3. Synthesis of complexes 5–8
3.1.3.1. Synthesis of [Ru(g6-arene)Cl2]2(L). To a solution of [Ru(g6-
arene)Cl2]2 (100 mg) in dichloromethane (20 mL), 1 equiv. of solid
L3 or L4 was added (5 and 7: 0.163 mmol, 6 and 8: 0.15 mmol). The
mixture was stirred at room temperature for 24 h. Then the
product was isolated by precipitation with diethyl ether and dried
in vacuo to afford an orange to red powder.
3.1.3.2. [Ru(g6-p-iPrC6H4Me)Cl2]2(1,10-(NC5H4CH2NHOC)2-C5H4FeC5H4)
(5). Yield: 62%, 105 mg. 1H NMR (400 MHz, CDCl3): d = 8.78 (d,
4H, NC5H4, 3J = 6.0 Hz), 8.05 (br, 2H, NH), 7.22 (d, 4H, NC5H4,
3J = 6.0 Hz), 5.36 (d, 4H, C6H4, 3J = 6.0 Hz), 5.15 (d, 4H, C6H4,
3J = 6.0 Hz), 4.78 (s, 4H, CHFc), 4.33 (s, 4H, CHFc), 4.29 (d, 4H, NHCH2,
3J = 4.4 Hz), 2.91 (sept, 2H, CH(CH3)2, 3J = 6.8 Hz), 1.95 (s, 6H, CH3),
1.26 (d, 12H, CH(CH3)2, 3J = 6.8 Hz). 13C{1H} NMR (100 MHz,
CDCl3): d = 170.87 (CONH), 154.23 (NC5H4), 151.70 (NC5H4),
123.29 (NC5H4), 103.27 (C-CH(CH3)2), 97.30 (C-CH3), 83.05, 81.93
(C6H4), 80.54, 72.09, 70.68 (CHFc), 41.62 (CH2), 30.70 (CH(CH3)2),
22.28 (CH(CH3)2), 18.27 (CH3). ESI-MS: m/z = 725.14
[MClC10H14–RuCl2]+. Anal. Calc. for C44H50FeN4O2Ru2Cl4 
,.
,
4,
2,
):
7
),
l.
;
4)
,
,
),
2,
).
0
–
7,
),
+
4)
s,
t,
,
s,
),
9,
),
e
a
e
e
e
l-
-
y,
-
-
e
lf
s
-
d
n
h
-
al
-
o
.
ls
-
y
-
e
i-
d
d
3
e
e
y
-
-
a
y
,
.
es
Table 2
Crystallographic and selected experimental data for 1  CHCl3 and 3
1  CHCl3 3
Chemical formula C28H31Cl5FeN2ORu C26H30Cl2FeN2O2Ru
Formula weight 745.72 630.34
Crystal system Monoclinic Triclinic
Space group P21/c (no. 14) P1 (no. 2)
Crystal color and shape Orange block Orange block
Crystal size 0.37  0.30  0.29 0.35  0.27  0.16
a (Å) 14.450(3) 11.8573(8)
b (Å) 27.116(5) 12.8274(9)
c (Å) 7.863(2) 19.0365(14)
a () 105.798(6)
b () 103.68(3) 103.102(6)
c () 96.764(5)
V (Å3) 2993.5(11) 2663.3(3)
Z 4 4
T (K) 203(2) 203(2)
Dcalc (g cm3) 1.655 1.572
l (mm1) 1.461 1.338
Scan range () 2.09 < h < 26.06 1.68 < 2h < 25.68
Unique reﬂections 5410 10045
Observed reﬂections [I > 2r(I)] 2509 6464
Rint 0.0692 0.0446
Final R indices [I > 2r(I)]a 0.0417, wR2 0.0831 0.0304, wR20.0535
R indices (all data) 0.1096, wR2 0.0937 0.0587, wR2 0.0568
Goodness-of-ﬁt 0.730 0.800
Max, Min Dq (e (Å3) 0.681, 1.290 0.416, 0.569
a Structures were reﬁned on F02: wR2 = [
P
[w (F02–Fc2)2]/
P
w (F02)2]1/2, where
w1=[
P
(F02)+(aP)2 + bP] and P = [max(F02, 0) + 2Fc2]/3.
6CH2Cl2 (1151.62) C, 46.93; H, 4.55; N, 4.87. Found: C, 46.55; H
4.85; N, 4.58%.
3.1.3.3. [Ru(g6-C6Me6)Cl2]2(1,10-(NC5H4CH2NHOC)2–C5H4FeC5H4) (6)
Yield: 79%, 133 mg. 1H NMR (400 MHz, CDCl3): d = 8.52 (d, 4H
NC5H4, 3J = 6.0 Hz), 7.92 (br, 2H, NH), 7.17 (d, 4H, NC5H
3J = 6.0 Hz), 4.74 (s, 4H, CHFc), 4.37 (s, 4H, CHFc), 4.34 (d, 4H, NHCH
3J = 5.6 Hz), 1.91 (s, 36H, CH3). 13C{1H} NMR (100 MHz, CDCl3
d = 171.06 (CONH), 153.89 (NC5H4), 151.67 (NC5H4), 123.4
(NC5H4), 91.43 (C-CH3), 75.91, 71.96, 70.95 (CHFc), 41.53 (CH2
15.64 (CH3). ESI-MS: m/z = 404.9 [M+3H+(CH3)2CO+MeOH]3+. Ana
Calc. for C48H58FeN4O2Ru2Cl4  CH2Cl2 (1207.73) C, 48.73; H, 5.01
N, 4.64. Found: C, 48.64; H, 5.39; N, 4.51%.
3.1.3.4. [Ru(g6-p-iPrC6H4Me)Cl2]2(1,10-(NC3H3N(CH2)2O2C)2–C5H4FeC5H
(7). Yield: 74%, 87 mg. 1H NMR (400 MHz, CDCl3): d = 8.13 (s, 2H
NC3H3N), 7.31 (s, 2H, NC3H3N), 7.05 (s, 2H, NC3H3N), 5.43 (d, 4H
C6H4, 3J = 5.4 Hz), 5.25 (d, 4H, C6H4, 3J = 5.4 Hz), 4.75 (s, 4H, CHFc
4,44 (s, 4H, CHFc), 4.22 (m, 8H, CH2), 2.93 (sept, 2H, CH(CH3)
3J = 6.8 Hz), 2.12 (s, 6H, CH3), 1.25 (d, 12H, CH(CH3)2, 3J = 6.8 Hz
13C{1H} NMR (100 MHz, CDCl3): d = 169.82 (COO), 140.5
(NC3H3N), 131.99 (NC3H3N), 120.44 (NC3H3N), 102.58 (C
CH(CH3)2), 97.38 (C–CH3), 82.68 (C6H4), 81.41 (C6H4), 72.9
72.38, 71.99 (CHFc), 63.10 (CH2), 47.44 (CH2), 30.70 (CH(CH3)2
22.36 (CH(CH3)2), 18.55 (CH3). ESI-MS: m/z = 564.13 [M+2H+H2O
MeOH]2+.
3.1.3.5. [Ru(g6-C6Me6)Cl2]2(1,10-(NC3H3N(CH2)2O2C)2–C5H4FeC5H
(8). Yield: 83%, 140 mg. 1H NMR (400 MHz, CDCl3): d = 8.13 (
2H, NC3H3N), 7.09 (s, 2H, NC3H3N), 6.99 (s, 2H, NC3H3N), 4.70 (
4H, CHFc, 3J = 2.0 Hz), 4.44 (t, 4H, CHFc, 3J = 2.0 Hz), 4.22 (t, 4H
COOCH2, 3J = 4.8 Hz), 3.89 (t, 4H, COOCH2CH2, 3J = 4.8 Hz), 2.01 (
36H, CH3). 13C{1H} NMR (100 MHz, CDCl3): d = 169.85 (COO
140.06 (NC3H3N), 131.30 (NC3H3N), 120.75 (NC3H3N), 93.0
90.96, 89.81 (C-CH3), 72.89, 72.65, 72.37 (CHFc), 63.50 (CH2
47.42 (CH2), 15.92 (CH3). ESI-MS: m/z = 1131.90 [M+H]+.
3.2. Single crystal X-ray structure analysis
Single crystals of 1  CHCl3 and 3were mounted on a Stoe Imag
Plate Diffraction equipped with a / circle goniometer, using Mo K
graphite monochromated radiation (k = 0.71073 Å) with / rang
0–200. The structures were solved by direct methods using th
program SHELXS-97 [29]. Reﬁnement and all further calculations wer
carried out using SHELXL-97 [30]. The H-atoms were included in ca
culated positions and treated as riding atoms using the SHELXL de
fault parameters. The non-H atoms were reﬁned anisotropicall
using weighted full-matrix least-square on F2. Crystallographic de
tails are summarized in Table 2. Figs. 1 and 3 were drawn with OR
TEP [31] and Fig. 2 with MERCURY [32].
3.3. Cytotoxicity study
The human A2780 ovarian cancer cell line was obtained from
the European Collection of Cell Cultures (Salisbury, UK). Cells wer
grown routinely in RPMI medium containing glucose, 5% foetal ca
serum (FCS) and antibiotics at 37 C and 5% CO2. Cytotoxicity wa
determined using the MTT assay (MTT = 3-(4,5-dimethyl-2-thiaz
olyl)-2,5-diphenyl-2 H-tetrazolium bromide). Cells were seede
in 96-well plates as monolayers with 100 lL of cell solutio
(approximately 20,000 cells) per well and pre-incubated for 24
in medium supplemented with 10% FCS. Compounds were dis
solved ﬁrst in DMSO and then added to the culture medium (ﬁn
DMSO concentration = 0.5% v/v) and serially diluted to the appro
priate concentration, 100 lL of compound solution was added t
each well and the plates were incubated for another 72 hSubsequently, MTT (5 mg/mL solution) was added to the cel
and the plates were incubated for a further 2 h. The culture med
ium was aspirated, and the purple formazan crystals formed b
the mitochondrial dehydrogenase activity of vital cells were dis
solved in DMSO. The optical density, directly proportional to th
number of surviving cells, was quantiﬁed at 540 nm using a mult
well plate reader and the fraction of surviving cells was calculate
from the absorbance of untreated control cells. Evaluation is base
on means from two independent experiments, each comprising
microcultures per concentration level.
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